- £229.97m
- £113.94m
- $38.63m
- 47
- 12
- 27
- 16
Annual cashflow statement for MaxCyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -11.8 | -19.1 | -23.6 | -37.9 | -41.1 |
| Depreciation | |||||
| Non-Cash Items | 2.93 | 8.69 | 9.3 | 7.55 | 9.88 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.942 | -1.71 | -3.21 | 4.52 | -0.751 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -8.78 | -10.7 | -14.8 | -21.7 | -27.6 |
| Capital Expenditures | -2.07 | -3.83 | -18.5 | -3.7 | -1.65 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -14.5 | -191 | -6.35 | 58.7 | 8.58 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -16.6 | -195 | -24.8 | 55 | 6.93 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 28.9 | 235 | 2.89 | 2.14 | 2.06 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.54 | 29 | -36.7 | 35.4 | -18.6 |